MiMedx Group, Inc. develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The company’s biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The company processes the human amniotic membrane utilizing its proprietary PURION Process, to produce an implant. It is a supplier of amniotic tissue, having supplied approximately 500,000 allografts to date for application in the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic and dental sectors of healthcare. The company introduced OrthoFlo, an amniotic fluid derived allograft for homologous use. Through the recent acquisition of Stability Inc. doing business as Stability Biologics, LLC (Stability), its newest proprietary platforms include Physio, a bone grafting material comprised of 100% bone tissue, a demineralized bone matrix (DBM) to complement its product portfolio offerings within the orthopedic market; and AlloBurn, a skin product for burns. CollaFix, the company's next technology platform it plans to commercialize, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues to augment their repair. Technology and Products AmnioFix, EpiFix and other Tissue-Based Allografts The company’s amniotic membrane products include its own brands, AmnioFix and EpiFix, as well as products that it supplies on a private label or OEM basis. It continues to research new opportunities for amniotic tissue, and has various additional offerings in various stages of conceptualization and development. EpiFix The company’s EpiFix allograft is configured for external use. It is used to improve healing, as well as to modulate inflammation. The EpiFix platform has been used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds. The company offers EpiFix in a sheet form, as well as a micronized powder form. AmnioFix The company’s AmnioFix allografts are configured for internal use. Its AmnioFix product line consists of three main configurations, AmnioFix, AmnioFix Wrap and AmnioFix Injectable. AmnioFix is provided in a sheet form. It is used to modulate inflammation, improve healing and to minimize scar tissue formation. It has been used in spine, urology and general surgeries. AmnioFix Wrap is also supplied in a sheet form and is configured for the same purposes as AmnioFix, but is optimized for use as a ‘wrap’ for nerves, tendons or ligaments. AmnioFix Injectable is supplied in micronized powder form used to reduce inflammation while improving healing. AmnioFix Injectable has been used to treat conditions, such as tendonitis, including plantar fasciitis, lateral epicondylitis, and medial epicondylitis, bursitis, strains and sprains. OEM Products Allografts for ophthalmic surgery and dental applications are sold on an OEM basis pursuant to agreements whereby it has granted third parties exclusive licenses to some of its technology for use in those fields in specified markets. The company also sells products on a non-exclusive OEM basis to Medtronic, Inc. for spinal procedures and Zimmer Biomet for spine and orthopedic procedures. OrthoFlo OrthoFlo is a human tissue allograft that is derived from amniotic fluid, donated by mothers delivering healthy babies by scheduled caesarean section;. It is for homologous use to protect and cushion, provide lubrication, and reduce inflammation. Amniotic fluid, in utero, naturally functions to protect, cushion and improve mobility. Key elements of amniotic fluid include growth factors, carbohydrates, proteins, lipids, electrolytes, and other nutrients, as well as hyaluronic acid (HA), a principal component of viscosity and lubrication in synovial fluid. A multitude of regulatory factors have been identified in amniotic fl
mimedx group inc
(MDXG:Consolidated Issue listed on NASDAQ Capital Market)
1775 West Oak Commons Court, NE
Marietta, GA 30062
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MDXG.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.